Back to search results

Brentuximab Vedotin for Early Stage Hodgkin Lymphoma

This study, called RADAR, is testing two different chemotherapy treatments for early stage Hodgkin Lymphoma (a type of cancer that affects the lymphatic system). You would receive either ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or A2VD (doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine). The study is looking to see how long people live without their cancer getting worse (progression-free survival) at 3 years after treatment. This study is for people aged 16 to 69 with newly diagnosed classical Hodgkin lymphoma that is in early stages and has not spread widely. The study is currently unclear on its recruitment status and plans to enroll 1042 participants.

Study design
This is a randomized, open-label study with two parallel trials, involving 1042 participants. You would be randomly assigned to one of the two treatment groups.
What's involved
You would receive chemotherapy and have PET-CT scans after 1 and 2 cycles of treatment. Depending on your response, you might have further chemotherapy cycles, involved site radiotherapy (focused radiation therapy), and a final PET-CT scan.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for a minimum of 5 years after completing treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04685616

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
PHASE3Ages 16–69InterventionalTreatment
University College, London
~1,042 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:Involved site radiotherapyDoxorubicinBleomycinBrentuximab vedotinVinblastineDacarbazine

At a glance

Recruiting sites
72 of 72 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression free survival (PFS)
Measured over 3 years from end of treatment

Conditions

Hodgkin Lymphoma

Explore related trials

Classic Hodgkin Lymphoma

Where it's being run

72 sites across 24 states
United Kingdom26
Australia8
Canada5
Netherlands5
Belgium4
Ireland3
Spain3
Denmark2

Study leadership

  • John Radford · PRINCIPAL_INVESTIGATOR · University of Manchester / Christie Hospital, Manchester

Who to contact

RADAR Trial Coordinator
[email protected]
+44(0)207 679 9860
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)
Histologically confirmed classical Hodgkin lymphoma
Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.
ECOG performance status 0-2.
No previous treatment for Hodgkin lymphoma
Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
Creatinine clearance (measured or calculated \>40ml/min
Total bilirubin \<1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome
ALT or AST \< 2 x upper limit of normal
Adequate bone marrow function with neutrophils ≥1.0x10\^9/l and platelets ≥100x10\^9/l
Haemoglobin ≥8g/dL
Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable
Written informed consent

Exclusion

Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
Infradiaphragmatic disease
Nodular lymphocyte predominant Hodgkin lymphoma
Absence of FDG-avid lesions on baseline PET scan
Age 70 years or over or age 15 years or under
Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded
Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis
Pre-existing grade ≥1 sensory or motor neuropathy from any cause
History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)
Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose
Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)
Pregnant or breastfeeding women
Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration
Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous

What this trial measures

  • Progression free survival (PFS)3 years from end of treatment

    Time from randomisation to first date of progression or death